Charles J. Parker,
MD, AB
Languages Spoken: English
Charles J. Parker, M. D., is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, at the University of Utah, the Huntsman Cancer Institute and the George E. Whalen VA Medical Center, Salt Lake City, UT. As a Hematologist, his clinical interests include paroxysmal nocturnal hemoglobinuria, hemochromatosis and porphyria.
Dr. Parker received his MD from The University of North Carolina, Chapel Hill. He received training in medicine and Hematology from the North Carolina Memorial Hospital, Chapel Hill and Duke University. In the past, Dr. Parker served as President of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group. He is currently Editor-in-Chief of The Hematologist.
For questions regarding Dr. Parker's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.
Clinical Locations
Hematology Clinic
801-585-2626
Fax: (801) 585-0309
801-581-2000
Veterans Administration Medical Center
Fax: (801) 583-9624
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Hematology) Educational Commission for Foreign Medical Graduates Licentiate of the Medical Council of Canada Royal College of Physicians and Surgeons of Canada Royal College of Surgeons of Canada |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.6/ 5
Care provider's explanation of condition/problem
4.6/ 5
Care provider's effort to include me in decisions
4.6/ 5
Wait time at clinic
4.1/ 5
Care provider's concern for questions & worries
4.6/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
August 01, 2021
SUGAR HOUSE HEALTH CENTER
Dr Parker's NP/PA was very kind and explained a lot to me about what was going on. However, when Dr Parker himself came in, he was barely in there for even 2 minutes and didn't explain anything to me! Just said that the blood work I came in for wasn't concerning, it may just be "my normal." Then he ordered extra blood tests, but he didn't give any other explanation as to why or the risks of my levels being abnormal. He just said that they would contact me the next day, which didn't happen. Anyway, thank you to Dr Parker's NP/PA for helping me out and for being so kind!
UofU Patient
July 24, 2021
SUGAR HOUSE HEALTH CENTER
My care providers did their best to allay any concerns, I may have. The unanswered segments do not apply at this time. I feel assured they will be diligent in trying to obtain a diagnoses.
UofU Patient
July 18, 2021
SUGAR HOUSE HEALTH CENTER
Always very good and I and my family are always happy with thier care for me
UofU Patient
May 25, 2021
SUGAR HOUSE HEALTH CENTER
Good experience
UofU Patient
May 24, 2021
SUGAR HOUSE HEALTH CENTER
need injection shots, nothing on the risks talked about
UofU Patient
January 20, 2021
SUGAR HOUSE HEALTH CENTER
Dr Parker is great
UofU Patient
October 26, 2020
SUGAR HOUSE HEALTH CENTER
Dr. Parker monitors my chronic condition and takes an interest in how I'm doing. I appreciate his watchfulness.
UofU Patient
September 25, 2020
SUGAR HOUSE HEALTH CENTER
The nurse practitioner listened to all of my questions and then left the screen to get responses from the doctor. She said she would return with his responses. After quite some time my doctor appeared on the screen. He. said that his nurse practitioner would take care of all the questions I had asked. I asked the doctor one other question that I thought of. We discussed this matter and he discussed medicine that I would take. I never heard from the n.p. She thought the doctor answered all questions. I sent an inquiry about responses to my questions. The n.p. told me of the confusion but I would still like to get answers to the questions I had.
UofU Patient
September 23, 2020
SUGAR HOUSE HEALTH CENTER
trying meds to improve my energy level
UofU Patient
August 16, 2020
SUGAR HOUSE HEALTH CENTER
we like Dr. Parker
UofU Patient
July 13, 2020
SUGAR HOUSE HEALTH CENTER
Had a great discussion and I fully understood everything she explained to me.
UofU Patient
May 18, 2020
SUGAR HOUSE HEALTH CENTER
so so
UofU Patient
April 06, 2020
SUGAR HOUSE HEALTH CENTER
He is excellent, very knowledgeable, patient, & willing to take the necessary time to explain any question you may have.
Charles J. Parker, M. D., is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, at the University of Utah, the Huntsman Cancer Institute and the George E. Whalen VA Medical Center, Salt Lake City, UT. As a Hematologist, his clinical interests include paroxysmal nocturnal hemoglobinuria, hemochromatosis and porphyria.
Dr. Parker received his MD from The University of North Carolina, Chapel Hill. He received training in medicine and Hematology from the North Carolina Memorial Hospital, Chapel Hill and Duke University. In the past, Dr. Parker served as President of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group. He is currently Editor-in-Chief of The Hematologist.
For questions regarding Dr. Parker's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 587-4630.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Hematology) Educational Commission for Foreign Medical Graduates Licentiate of the Medical Council of Canada Royal College of Physicians and Surgeons of Canada Royal College of Surgeons of Canada |
Research Interests
- Paroxysmal Nocturnal Hemoglobinuria
- Myeloproliferative Disorders
Education History
| Fellowship | Duke University Medical Center Hematology/Oncology Fellow, 1981 |
| Residency | North Carolina Memorial Hospital Internal Medicine Resident, 1978 |
| Internship | North Carolina Memorial Hospital Intern, 1976 |
| Professional Medical | University of North Carolina Medicine M.D., 1975 |
| Undergraduate | University of North Carolina English A.B., 1970 |
Selected Publications - Journal Articles
Journal Article
- Farrell CP, Nicolas G, Desnick RJ, Parker CJ, Lamoril J, Gouya L, Karim Z, Tchernitchko D, Chen B, Puy H, Phillips JD (2021). ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. (Epub ahead of print) Blood Adv.
- Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. (Epub ahead of print) Blood Coagul Fibrinolysis.
- Thiagarajan P, Parker CJ, Prchal JT (2021). How Do Red Blood Cells Die? Front Physiol, 12, 655393.
- Parker CJ, Desnick RJ, Bissel MD, Bloomer JR, Singal A, Gouya L, Puy H, Anderson KE, Balwani M, Phillips JD (2019). Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Mol Genet Metab, 128(3), 309-313.
- Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM (2014). Liver transplantation in the management of porphyria. Hepatology, 60(3), 1082-9.
- Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9.
- Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ (2010). In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol, 39(1), 14-25.
- Parker CJ, Brodsky RA, Levine JE (2009). Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant, 15(1 Suppl), 72-8.
- Parker CJ, Janatova J, Weis JH (2000). Preface. Immunopharmacology, 49(1-2), 99-100.
- Bohnsack JF, Widjaja K, Ghazizadeh S, Rubens CE, Hillyard DR, Parker CJ, Albertine KH, Hill HR (1997). A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections. J Infect Dis, 175(4), 847-55.
- Liu L, Murray DK, Dameron CT, Parker CJ, Rodgers GM (1997). Biochemical characterization of procoagulant albumin. Thromb Res, 85(5), 399-411.
- Gubler DB, Ahlstrom CR, Liu L, Zhou JF, Parker CJ, Rodgers GM (1995). Procoagulant albumin increases vascular endothelial cell prostacyclin secretion. Thromb Haemost, 74(6), 1573-7.
- Grosset A, Liu L, Parker CJ, Rodgers GM (1994). Bioassay of procoagulant albumin in human plasma. Thromb Res, 75(5), 551-8.
- Tomita A, Radike EL, Parker CJ (1993). Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A. J Immunol, 151(6), 3308-23.
- Gubler DB, Wilson BD, Parker CJ, Rodgers GM (1993). Regulation of endothelial cell protein C activation and fibrinolysis by procoagulant albumin. Thromb Res, 70(6), 459-69.
- Ezzell JL, Parker CJ (1992). Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity. Scand J Immunol, 36(1), 79-87.
- Bohnsack JF, Zhou XN, Gustin JN, Rubens CE, Parker CJ, Hill HR (1992). Bacterial evasion of the antibody response: human IgG antibodies neutralize soluble but not bacteria-associated group B streptococcal C5a-ase. J Infect Dis, 165(2), 315-21.
- Holguin MH, Martin CB, Bernshaw NJ, Parker CJ (1992). Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. J Immunol, 148(2), 498-502.
- Bohnsack JF, Zhou XN, Williams PA, Cleary PP, Parker CJ, Hill HR (1991). Purification of the proteinase from group B streptococci that inactivates human C5a. Biochim Biophys Acta, 1079(2), 222-8.
- Janatova J, Cheung AK, Parker CJ (1991). Biomedical polymers differ in their capacity to activate complement. Complement Inflamm, 8(2), 61-9.
- Lassiter HA, Speranza MJ, Hall RT, Meade V, Christensen RD, Parker CJ (1990). Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin. J Perinatol, 10(1), 27-31.
- Parker CJ, Bernshaw NJ, Wilcox LA (1990). Analysis of the binding of human C3b to glycoproteins on rabbit and sheep erythrocytes. Complement Inflamm, 7(1), 1-17.
- Cheung AK, Parker CJ, Wilcox L (1989). Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure. Clin Exp Immunol, 78(2), 299-306.
- Lassiter HA, Christensen RD, Parker CJ (1989). Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG. J Infect Dis, 159(3), 518-25.
- Parker CJ, Stone OL, Bernshaw NJ (1989). Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor. J Immunol, 142(1), 208-16.
- Hill HR, Bohnsack JF, Morris EZ, Augustine NH, Parker CJ, Cleary PP, Wu JT (1988). Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol, 141(10), 3551-6.
- Whatley RE, Lewis MS, Zimmerman GA, McIntyre TM, Parker CJ, Stevens DL, Prescott SM (1988). The regulation of synthesis of platelet-activating factor by endothelial cells. Chest, 93(3 Suppl), 110S-111S.
Review
- Parker CJ (2012). Paroxysmal nocturnal hemoglobinuria. [Review]. Curr Opin Hematol, 19(3), 141-8.
- Parker CJ (2011). Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. [Review]. Hematology Am Soc Hematol Educ Program, 2011, 21-9.
- Parker, CJ (2011). Complement and hematology. [Review]. The Hematologist, 8(1), 5.
Book Chapter
- Parker CJ (2017). Complement and PNH. In Kanakura Y, Kinoshita T, Nishimura J (Eds.), Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bedside (pp. 67-98). Tokyo: Springer Japan KK.
- Parker CJ (2015). Paroxysmal Nocturnal Hemoglobinuria. In Kaushansky K, Lichtman M, Kipps T, Prchal J, Seligsohn U (Eds.), Williams Hematology (9th Edition). Boston: McGraw-Hill.
- Parker CJ (2015). Complement for the Clinician. In Brodsky R (Ed.), Complement-mediated Hemolytic Anemias, An Issue of Hematology/Oncology Clinics of North America. Philadelphia: Elsevier.
- Parker CJ, Ware RE (2014). Paroxysmal Nocturnal Hemoglobinuria. In Orkin S, Nathan G, Ginsburg D, Look AT, Fisher D, Lux S (Eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood (8th Edition). Philadelphia: Elsevier.
- Parker, CJ and Ware, RE (2013). Paroxysmal nocturnal hemoglobinuria. In Greer J, Arber D, Glader B, List A, Means R, Paraskevas F, Rodgers G, Foerster J (Eds.), Wintrobe's Clinical Hematology (13th Ed, pp. 785-808). Philadelphia: Lippincott Williams & Wilkins.